2-methyl-4-phenylnicotinic acid | 1256643-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-methyl-4-phenylnicotinic acid
• 英文别名: 2-methyl-4-phenylpyridine-3-carboxylic acid
• CAS: 1256643-39-6
• 化学式: C₁₃H₁₁NO₂
• mdl: MFCD18381942
• 分子量: 213.236
• InChiKey: FSMZYQNQFJDUJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  2-methyl-4-phenylnicotinic acid 在 氯化亚砜 、 一水合肼 、 三乙胺 、 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 反应 39.0h， 生成 N-[3,5-bis(trifluoromethyl)benzyl]-5-methyl-7-phenyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxamide
  参考文献：
  名称：

  Non-peptide NK1 receptor ligands based on the 4-phenylpyridine moiety

  摘要：

  The quinoline nucleus of the previously described 4-phenylquinoline-3-carboxamides NK1 receptor ligands 7 has been transformed into either substituted or azole-(i.e., triazole or tetrazole) fused pyridine moieties of compounds 9 and 10, respectively, in order to obtain NK1 receptor ligands showing lower molecular weight or higher hydrophilicity. The program of molecular manipulations produced NK1 receptor ligands showing affinity in the nanomolar range. In particular, 4-methyl-1-piperazinyl derivative 9j showed an IC50 value of 4.8 nM and was proved to behave as a NK1 antagonist blocking Sar(9)-SP-sulfone induced proliferation and migration of microvascular endothelial cells. Therefore, compound 9j has been labeled with [C-11]CH3I (t(1/2) = 20.4 min, beta(+) = 99.8%) starting from the corresponding des-methyl precursor 9i using with a radiochemical yield of about 10% (not decay corrected) and a specific radioactivity > 1 Ci/mu mol in order to be used as a radiotracer in next PET studies. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.02.031
• 作为产物：
  描述：

  反式肉桂醛 在 哌啶 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 2-methyl-4-phenylnicotinic acid
  参考文献：
  名称：

  Non-peptide NK1 receptor ligands based on the 4-phenylpyridine moiety

  摘要：

  The quinoline nucleus of the previously described 4-phenylquinoline-3-carboxamides NK1 receptor ligands 7 has been transformed into either substituted or azole-(i.e., triazole or tetrazole) fused pyridine moieties of compounds 9 and 10, respectively, in order to obtain NK1 receptor ligands showing lower molecular weight or higher hydrophilicity. The program of molecular manipulations produced NK1 receptor ligands showing affinity in the nanomolar range. In particular, 4-methyl-1-piperazinyl derivative 9j showed an IC50 value of 4.8 nM and was proved to behave as a NK1 antagonist blocking Sar(9)-SP-sulfone induced proliferation and migration of microvascular endothelial cells. Therefore, compound 9j has been labeled with [C-11]CH3I (t(1/2) = 20.4 min, beta(+) = 99.8%) starting from the corresponding des-methyl precursor 9i using with a radiochemical yield of about 10% (not decay corrected) and a specific radioactivity > 1 Ci/mu mol in order to be used as a radiotracer in next PET studies. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.02.031

文献信息

• BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Merck & Co., Inc.

  公开号：EP1855670A2

  公开（公告）日：2007-11-21
• [EN] BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] POTENTIALISATEURS DE BENZAZOLE DE RECEPTEURS DE GLUTAMATE METABOTROPIQUE
  申请人：MERCK & CO INC

  公开号：WO2006091496A2

  公开（公告）日：2006-08-31

  [EN] The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
  [FR] L'invention se rapporte à des composés de benzazole qui sont des potentialisateurs de récepteurs de glutamate métabotropique, y compris le récepteur mGluR2, et qui sont utiles dans le traitement ou la prévention de troubles neurologiques et psychiatriques associés au dysfonctionnement du glutamate et aux maladies dans lesquelles les récepteurs de glutamate métabotropique sont impliqués. Cette invention concerne aussi des compositions pharmaceutiques contenant ces composés, ainsi que l'utilisation de ces composés et compositions dans la prévention ou le traitement des maladies dans lesquelles les récepteurs de glutamate métabotropique sont impliqués.